Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients

British Journal of Clinical Pharmacology

Volumn 77, Issue 1, 2014, Pages 201-210

  Cahir, Caitriona ^a   Bennett, Kathleen ^a   Teljeur, Conor ^b   Fahey, Tom ^c  

^a ST JAMES S HOSPITAL   (Ireland)

^b HEALTH INFORMATION AND QUALITY AUTHORITY   (Ireland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

adverse drug events; health care use; HRQOL; older populations; potentially inappropriate prescribing; STOPP

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMLODIPINE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CENTRAL STIMULANT AGENT; CODEINE; DICLOFENAC; DOXEPIN; FUROSEMIDE; IBUPROFEN; LERCANIDIPINE; MISOPROSTOL; PRAVASTATIN; PROTON PUMP INHIBITOR; TRAMADOL; TRIFLUOPERAZINE; WARFARIN;

ADVERSE OUTCOME; AGED; ARTICLE; BALANCE DISORDER; BLEEDING; BRONCHOSPASM; CONFUSION; CONSTIPATION; DIZZINESS; EQ 5D; FALLING; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEARTBURN; HUMAN; INAPPROPRIATE PRESCRIBING; INDIGESTION; IRELAND; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PEPTIC ULCER; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEDATION; SELF REPORT; SIDE EFFECT; SKIN BRUISING; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; UNSTEADINESS; AGING; DEMOGRAPHY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH STATUS; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH STATUS; HUMANS; INAPPROPRIATE PRESCRIBING; IRELAND; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; PREVALENCE; QUALITY OF LIFE; RESIDENCE CHARACTERISTICS;

EID: 84891097744     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12161     Document Type: Article

References (41)

1. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT,. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007; 370: 173-184.
2. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW,. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289: 1107-1116.
3. Budnitz DS, Lovegrove MC, Shehab N, Richards CL,. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012.
4. Routledge PA, Mahony MSO, Woodhouse KW,. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004; 57: 121-126.
5. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH,. Updating the beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716-2724.
6. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D,. STOPP (Screening tool of older person's prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther 2008; 46: 72-83.
7. Pyszka LL, Seys Ranola TM, Milhans SM,. Identification of inappropriate prescribing in geriatrics at a veterans affairs hospital using STOPP/START screening tools. Consult Pharm 2010; 25: 365-373.
8. Gallagher P, Lang P, Cherubini A, Topinková E, Cruz-Jentoft A, Montero Errasquín B, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol 2011; 67: 1175-1188.
9. Liu C-L, Peng L-N, Chen Y-T, Lin M-H, Liu L-K, Chen L-K,. Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: a hospital-based study. Arch Gerontol Geriatr 2012; 55: 148-151.
10. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K,. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol 2010; 69: 543-552.
11. Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D,. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011; 171: 1013-1019.
12. Naughton C, Bennett K, Feely J,. Prevalence of chronic disease in the elderly based on a national pharmacy claims database. Age Ageing 2006; 35: 633-636.
13. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2010.
14. Parry G, Cline A, Goldman D,. Deciphering harm measurement. JAMA 2012; 307: 2155-2156.
15. Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A,. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002; 53: 318-325.
16. Chrischilles EA, VanGilder R, Wright K, Kelly M, Wallace RB,. Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. J Am Geriatr Soc 2009; 57: 1000-1006.
17. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW,. Adverse drug events in ambulatory care. N Engl J Med 2003; 348: 1556-1564.
18. Landis J, Koch G,. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
19. The EuroQol Group. EuroQol- A new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
20. Grundy E, Holt G,. The socioeconomic status of older adults: how should we measure it in studies of health inequalities? J Epidemiol Community Health 2001; 55: 895-904.
21. Charlson M, Pompei P, Ales K, MacKenzie C,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
22. Sherbourne CD, Stewart AL,. The MOS social support survey. Soc Sci Med 1991; 32: 705-714.
23. Lubben J, Blozik E, Gillmann G, Iliffe S, von Renteln Kruse W, Beck JC, Stuck AE,. Performance of an abbreviated version of the lubben social network scale among three european community-dwelling older adult populations. Gerontologist 2006; 46: 503-513.
24. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M,. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12.
25. Morisky DE, Ward HJ, Liu KY,. Self-reported medication taking behaviour: a valid indicator for assessing compliance. In 129th American Public Health Association Meeting. Atlanta, 2001.
26. Hanlon JT, Schmader KE,. What types of inappropriate prescribing predict adverse drug reactions in older adults? Ann Pharmacother 2010; 44: 1110-1111.
27. Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ,. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother 2010; 44: 957-963.
28. Gelman A, Hall J,. Data Analysis Using Regression and Multilevel/Hierarchial Models. London: Cambridge University Press, 2003.
29. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, Lau GKK, Wong WM, Yuen MF, Chan AOO, Lai CL, Wong J,. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-2038.
30. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM,. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
31. Shehab N, Sperling LS, Keqler SR, Budnitz DS,. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med 2010; 170: 1926-1933.
32. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M,. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63: 136-147.
33. Fick DM, Waller JL, Maclean JR, Heuvel RV, Tadlock JG, Gottlieb M, Cangialose CB,. Potentially inappropriate medication use in a medicare managed care population: association with higher costs and utilization. J Manag Care Pharm 2001; 7: 407-413.
34. Walters S, Brazier J,. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005; 14: 1523-1532.
35. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK,. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 4: 70-75.
36. Perera S, Studenski S, Chandler JM, Guralnik JM,. Magnitude and patterns of decline in health and function in 1 year affect subsequent 5-year survival. J Gerontol A Biol Sci Med Sci 2005; 60: 894-900.
37. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K,. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ 2011; 342: d3514.
38. Garfinkel D, Mangin D,. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med 2010; 170: 1648-1654.
39. Clyne B, Bradley M, Smith SM, Hughes CM, Motterlini N, Clear D, McDonnell R, Williams D, Fahey T, OPTI-SCRIPT Study Team. Effectiveness of medicines review with web-based pharmaceutical treatment algorithms in reducing potentially inappropriate prescribing in older people in primary care: a cluster randomized trial (OPTI-SCRIPT study protocol). BMC Trials 2013; 14: 72.
40. Weingart SN, Gandhi TK, Seger AC, Seger DL, Borus J, Burdick E, Leape LL, Bates DW,. Patient-reported medication symptoms in primary care. Arch Intern Med 2005; 165: 234-240.
41. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE,. Beyond the prescription: medication monitoring and adverse drug events in older adults. J Am Geriatr Soc 2011; 59: 1513-1520.